ProSomnus raises $38M to advance oral sleep apnea device — non-CPAP alternative market growing rapidly post-Inspire V
Summary
ProSomnus secured $38M in financing in early 2026 to advance its precision oral sleep apnea devices — mandibular advancement devices that keep the airway open without CPAP. The OSA device market is expanding rapidly as Inspire Medical's hypoglossal nerve stimulator demonstrates the $10B+ opportunity in non-CPAP alternatives, and the £137B annual economic burden study provides the health economics foundation for payer engagement. ProSomnus targets the large CPAP-intolerant or CPAP-abandoning patient population.
Why it matters
Inspire Medical's commercial success (and $4B+ market cap) in non-CPAP OSA treatment has validated the entire category for investors and created a rising tide for all non-CPAP OSA competitors. ProSomnus's oral device offers a less invasive, lower-cost entry point than Inspire's surgical implant — positioning it as the bridge between CPAP and surgical HNS for the large middle market of CPAP non-adherent patients.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial